Bibliographic Details
| Title: |
The pan-cancer landscape of prognostic germline variants in 10,582 patients. |
| Authors: |
Chatrath, Ajay1 (AUTHOR), Przanowska, Roza1 (AUTHOR), Kiran, Shashi1 (AUTHOR), Su, Zhangli1 (AUTHOR), Saha, Shekhar1 (AUTHOR), Wilson, Briana1 (AUTHOR), Tsunematsu, Takaaki1 (AUTHOR), Ahn, Ji-Hye1 (AUTHOR), Lee, Kyung Yong1 (AUTHOR), Paulsen, Teressa1 (AUTHOR), Sobierajska, Ewelina1 (AUTHOR), Kiran, Manjari2 (AUTHOR), Tang, Xiwei3 (AUTHOR), Li, Tianxi3 (AUTHOR), Kumar, Pankaj1 (AUTHOR), Ratan, Aakrosh4 (AUTHOR), Dutta, Anindya1 (AUTHOR) ad8q@virginia.edu |
| Source: |
Genome Medicine. 2/17/2020, Vol. 12 Issue 1, p1-18. 18p. |
| Subject Terms: |
*PHARMACOGENOMICS, *TUMOR suppressor genes, *CANCER genes, *PROTEIN structure, *CANCER, *GENE expression, *GERM cells |
| Abstract: |
Background: While clinical factors such as age, grade, stage, and histological subtype provide physicians with information about patient prognosis, genomic data can further improve these predictions. Previous studies have shown that germline variants in known cancer driver genes are predictive of patient outcome, but no study has systematically analyzed multiple cancers in an unbiased way to identify genetic loci that can improve patient outcome predictions made using clinical factors. Methods: We analyzed sequencing data from the over 10,000 cancer patients available through The Cancer Genome Atlas to identify germline variants associated with patient outcome using multivariate Cox regression models. Results: We identified 79 prognostic germline variants in individual cancers and 112 prognostic germline variants in groups of cancers. The germline variants identified in individual cancers provide additional predictive power about patient outcomes beyond clinical information currently in use and may therefore augment clinical decisions based on expected tumor aggressiveness. Molecularly, at least 12 of the germline variants are likely associated with patient outcome through perturbation of protein structure and at least five through association with gene expression differences. Almost half of these germline variants are in previously reported tumor suppressors, oncogenes or cancer driver genes with the other half pointing to genomic loci that should be further investigated for their roles in cancers. Conclusions: Germline variants are predictive of outcome in cancer patients and specific germline variants can improve patient outcome predictions beyond predictions made using clinical factors alone. The germline variants also implicate new means by which known oncogenes, tumor suppressor genes, and driver genes are perturbed in cancer and suggest roles in cancer for other genes that have not been extensively studied in oncology. Further studies in other cancer cohorts are necessary to confirm that germline variation is associated with outcome in cancer patients as this is a proof-of-principle study. [ABSTRACT FROM AUTHOR] |
|
Copyright of Genome Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
